Molecular Cancer (Nov 2021)
Liquid biopsy identifies actionable dynamic predictors of resistance to Trastuzumab Emtansine (T-DM1) in advanced HER2-positive breast cancer
- Matteo Allegretti,
- Alessandra Fabi,
- Elena Giordani,
- Cristiana Ercolani,
- Paolo Romania,
- Cecilia Nisticò,
- Simona Gasparro,
- Vittoria Barberi,
- Maria Ciolina,
- Edoardo Pescarmona,
- Diana Giannarelli,
- Gennaro Ciliberto,
- Francesco Cognetti,
- Patrizio Giacomini
Affiliations
- Matteo Allegretti
- Oncogenomics and Epigenetics, IRCSS Regina Elena National Cancer Institute
- Alessandra Fabi
- Medical Oncology 1, IRCSS Regina Elena National Cancer Institute
- Elena Giordani
- Oncogenomics and Epigenetics, IRCSS Regina Elena National Cancer Institute
- Cristiana Ercolani
- Pathology, IRCSS Regina Elena National Cancer Institute
- Paolo Romania
- Oncogenomics and Epigenetics, IRCSS Regina Elena National Cancer Institute
- Cecilia Nisticò
- Medical Oncology 1, IRCSS Regina Elena National Cancer Institute
- Simona Gasparro
- Medical Oncology 1, IRCSS Regina Elena National Cancer Institute
- Vittoria Barberi
- Specialization School in Oncology, Sapienza University of Rome
- Maria Ciolina
- Radiology and Diagnostic Imaging, IRCSS Regina Elena National Cancer Institute
- Edoardo Pescarmona
- Pathology, IRCSS Regina Elena National Cancer Institute
- Diana Giannarelli
- Biostatistical Unit, IRCSS Regina Elena National Cancer Institute
- Gennaro Ciliberto
- Scientific Direction, IRCSS Regina Elena National Cancer Institute
- Francesco Cognetti
- Clinical and Molecular Medicine, Sapienza University of Rome
- Patrizio Giacomini
- Oncogenomics and Epigenetics, IRCSS Regina Elena National Cancer Institute
- DOI
- https://doi.org/10.1186/s12943-021-01438-z
- Journal volume & issue
-
Vol. 20,
no. 1
pp. 1 – 6
Abstract
No abstracts available.Keywords
